Drugs / Loncastuximab Tesirine
Loncastuximab Tesirine
also known as
ADCT-402 · ADCT-402 TESIRINE · Lonca · Loncastuximab tesirina · loncastuximab tesirine-lpyl · Zynlonta
Other / unclassified targets CD19 via depletion
Regulatory milestones approvals, filings & regulatory actions · 3 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Filed diffuse large B-cell lymphoma 2 milestones | |||||
| Filed | China (NMPA) | ZYNLONTA | diffuse large B-cell lymphoma | 2023-07-24 | “China National Medical Products Administration (NMPA) has accepted the Biologics License Application (BLA) for ZYNLONTA” adctherapeutics.com ↗ |
| Filed | EU (EMA) | ZYNLONTA | diffuse large B-cell lymphoma | — | “The medicine has orphan drug designation in the EU and is under regulatory review with a decision anticipated in the first quarter of 2023.” sobi.com ↗ “In the EU, loncastuximab tesirine has orphan drug designation for the treatment of DLBCL and is under regulatory review since October 2021.” sobi.com ↗ |
| Approved Indication not stated 1 milestone | |||||
| Approved · conditional | EU (EMA) | Zynlonta | — | 2022-12-20 | europa.eu ↗ |
Trials 32
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 111 trials | ||||||
| Phase 1 | NCT06607549 | Mar 2025 → Nov 2029 expected | central nervous system non-hodgkin lymphoma | University of Utah | Recruiting | No outcome recorded |
| Phase 1 | NCT05971251 | Dec 2023 → Dec 2026 expected | chronic lymphocytic leukemia/small lymphocytic lymphoma | University of Alabama at Birmingham | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05660395 | Jul 2023 → Jun 2026 | high grade B-cell lymphoma | ADC Therapeutics S.A. | Terminated | No outcome recorded |
| Phase 1 | NCT05228249 | Apr 2023 → Oct 2025 | high grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangement, primary mediastinal large B-cell lymphoma | Fred Hutchinson Cancer Center | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT05270057 | Jan 2023 → May 2025 overdue | Burkitt lymphoma | Medical College of Wisconsin | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05053659 | Jun 2022 → Nov 2026 expected | non-Hodgkin lymphoma | Paolo Caimi, MD | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04970901 | Jun 2022 → Mar 2027 expected | B-cell non-Hodgkin lymphoma | ADC Therapeutics S.A. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04974996 | Feb 2022 → Mar 2024 | diffuse large B-cell lymphoma | ADC Therapeutics S.A. | Withdrawn | No outcome recorded |
| Phase 1 | NCT03685344 | Feb 2019 → Oct 2020 | diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma | ADC Therapeutics S.A. | Terminated | No outcome recorded |
| Phase 1 | NCT02669264 | Mar 2016 → Jul 2018 | acute lymphoblastic leukemia | ADC Therapeutics S.A. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT02669017 | Mar 2016 → Feb 2019 | B-cell chronic lymphocytic leukemia, Burkitt lymphoma, Waldenstrom macroglobulinemia, follicular lymphoma +3 | ADC Therapeutics S.A. | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT07573436 | Nov 2026 → Jun 2030 expected | post-transplant lymphoproliferative disease | University of Utah | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT03684694 | Dec 2018 → Nov 2022 | diffuse large B-cell lymphoma, mantle cell lymphoma | ADC Therapeutics S.A. | Terminated | No outcome recorded |
| Phase 216 trials · 1 met primary | ||||||
| Phase 2 | NCT06919939 | Jan 2026 → Jan 2031 expected | diffuse large B-cell lymphoma, large B-cell lymphoma | University of Miami | Recruiting | No outcome recorded |
| Phase 2 | NCT07197307 | Oct 2025 → Jan 2030 expected | high grade B-cell lymphoma | University of Münster | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06788964 | Aug 2025 → Mar 2027 expected | large B-cell lymphoma | University of Utah | Recruiting | No outcome recorded |
| Phase 2 | NCT05672251 | Jan 2024 → Aug 2029 expected | Richter transformation, high grade B-cell lymphoma, primary mediastinal large B-cell lymphoma | City of Hope Medical Center | Recruiting | No outcome recorded |
| Phase 2 | NCT05453396 | Aug 2023 → May 2026 | diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma | University of Washington | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT06918912 | Jun 2023 → Mar 2025 overdue | high grade B-cell lymphoma | Istituto Clinico Humanitas | Recruiting | No outcome recorded |
| Phase 2 | NCT05600686 | May 2023 → Oct 2026 expected | diffuse large B-cell lymphoma, high grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangement | University of California, Davis | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05464719 | Sep 2022 → Jan 2030 expected | large B-cell lymphoma | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT05144009 | Jun 2022 → Jan 2024 | diffuse large B-cell lymphoma | ADC Therapeutics S.A. | Terminated | No outcome recorded |
| Phase 2 | NCT05296070 | Jun 2022 → Jun 2028 expected | marginal zone lymphoma | University of Miami | Recruiting | No outcome recorded |
| Phase 2 | NCT05222438 | Apr 2022 → Dec 2025 | diffuse large B-cell lymphoma | Barbara Ann Karmanos Cancer Institute | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT05249959 | Mar 2022 → Mar 2026 overdue | mantle cell lymphoma | Fondazione Italiana Linfomi - ETS | Recruiting | No outcome recorded |
| Phase 2 | NCT05190705 | Feb 2022 → May 2026 overdue | Waldenstrom macroglobulinemia | Shayna Sarosiek, MD | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04998669 | Feb 2022 → Aug 2027 expected | follicular lymphoma | Juan P. Alderuccio, MD | Recruiting | No outcome recorded |
| Phase 2 | NCT04699461 | Nov 2021 → Nov 2022 | follicular lymphoma | ADC Therapeutics S.A. | Terminated | No outcome recorded |
| Phase 2 | NCT03589469 | Aug 2018 → May 2020 | diffuse large B-cell lymphoma | ADC Therapeutics S.A. | Completed | Met primary |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05991388 | May 2024 → May 2031 expected | B-cell non-Hodgkin lymphoma | University of Birmingham | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04384484 | Sep 2020 → Mar 2026 overdue | diffuse large B-cell lymphoma | ADC Therapeutics S.A. | Active not recruiting | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT04705454 | — | relapsed/refractory diffuse large B-cell lymphoma | ADC Therapeutics S.A. | No longer available | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT07308132 Background | Jan 2026 → Aug 2028 expected | non-Hodgkin lymphoma | Janssen Research & Development, LLC | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 33
| Date | Issuer | Release |
|---|---|---|
| 2026-06-03 | ADC Therapeutics S.A. | Results ADC Therapeutics Announces Results From LOTIS-5 Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma adctherapeutics.com ↗
ZYNLONTA plus rituximab achieved statistical significance on the trial's primary endpoint of progression-free survival (PFS) and demonstrated no detrimental effect on the key secondary efficacy endpoint of overall survival (OS). |
| 2026-01-29 | Tanabe Pharma Corporation | Results MT-2111 (loncastuximab tesirine-lpyl) Achieved Primary Endpoint in Phase 2 part of Japanese Phase 1/2 study for Relapsed or Refractory Diffuse Large B-cell Lymphoma tanabe-pharma.com ↗
MT-2111 (loncastuximab tesirine-lpyl) Achieved Primary Endpoint in Phase 2 part of Japanese Phase 1/2 study for Relapsed or Refractory Diffuse Large B-cell Lymphoma |
| 2025-05-14 | ADC Therapeutics S.A. | Results ADC Therapeutics Announces Presentation of LOTIS-7 Clinical Trial Data at the European Hematology Association 2025 Congress (EHA2025) and the 18th International Conference on Malignant Lymphoma (ICML) adctherapeutics.com ↗
ZYNLONTA ® plus glofitamab (COLUMVI ® ) demonstrated ORR of 95.5% and CR of 90.9%, among 22 evaluable patients with relapsed/refractory DLBCL |
| 2024-12-09 | ADC Therapeutics S.A. | Results ADC Therapeutics Announces The Lancet Haematology Publication of Data from Investigator-Initiated Trial Evaluating ZYNLONTA® in Combination with Rituximab to Treat Relapsed/Refractory Follicular Lymphoma adctherapeutics.com ↗
Combination in r/r follicular lymphoma shows best ORR of 97% and CR rate of 77% with 12-month PFS of 95% |
| 2024-05-06 | ADC Therapeutics S.A. | Results ADC Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates adctherapeutics.com ↗
Initial MZL IIT Phase 2 data from 15 patients showed 13 patients with CR and 1 patient with PR; encouraging data compared to current treatments in area with high unmet medical need |
| 2024-05-06 | ADC Therapeutics S.A. | Results ADC Therapeutics Announces Initial Data from Investigator-Initiated Phase 2 Clinical Trial of ZYNLONTA® in Patients with Relapsed/Refractory Marginal Zone Lymphoma adctherapeutics.com ↗
Of these 15 patients evaluated, 13 achieved a complete response (CR) and one patient achieved a partial response (PR). |
| 2024-04-04 | ADC Therapeutics S.A. | Results ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma adctherapeutics.com ↗
Additionally, after the first investigator assessment, evidence of anti-tumor activity was observed among the majority of patients, with mixed histologies including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and marginal zone lymphoma (MZL). |
| 2024-01-04 | ADC Therapeutics S.A. | Results ADC Therapeutics Provides Business Updates adctherapeutics.com ↗
We are also encouraged to see positive initial signals in the LOTIS-7 trial of ZYNLONTA in combination with bispecifics as well as early signs of antitumor activity in the Phase 1b trial of ADCT-601. |
| 2023-12-12 | ADC Therapeutics S.A. | Results ADC Therapeutics Announces Initial Results from Investigator-Initiated Phase 2 Clinical Trial Evaluating ZYNLONTA® in Combination with Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma (FL) adctherapeutics.com ↗ |
| 2023-11-02 | ADC Therapeutics S.A. | Results ADC Therapeutics Announces Abstracts Accepted for Presentation at the 65th ASH Annual Meeting adctherapeutics.com ↗
The combination was well tolerated with a 95% overall response rate at week 12 and at week 21, an 86% metabolic complete response rate. |
| 2023-08-30 | ADC Therapeutics S.A. | Results ADC Therapeutics Announces Updates on ZYNLONTA® LOTIS Clinical Trial Programs at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) adctherapeutics.com ↗ |
| 2023-07-24 | ADC Therapeutics S.A. | Regulatory Overland ADCT BioPharma Announces NMPA Accepts Biologics License Application and Grants Priority Review for ZYNLONTA® for Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma adctherapeutics.com ↗
The BLA has been granted priority review by the NMPA. |
| 2023-07-11 | ADC Therapeutics S.A. | Results ADC Therapeutics Announces Voluntary Pause of Enrollment in the Phase 2 LOTIS-9 Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) and Rituximab in Unfit or Frail Previously Untreated DLBCL Patients adctherapeutics.com ↗
The voluntary action was taken by the Company after a recent review of aggregate data of the 40 patients enrolled in the trial and consultation with the Data Monitoring Committee (DMC) which signaled potentially excessive respiratory-related events. |
| 2023-06-09 | ADC Therapeutics S.A. | Results ADC Therapeutics Announces Updated LOTIS-2 Results Demonstrating Durable, Long-Term Responses of ZYNLONTA® in Relapsed/Refractory DLBCL adctherapeutics.com ↗
ADC Therapeutics SA (NYSE: ADCT) today announced updated results from LOTIS-2, the pivotal Phase 2 clinical trial of ZYNLONTA ® (loncastuximab tesirine-lpyl) in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). |
| 2023-05-11 | ADC Therapeutics S.A. | Results ADC Therapeutics Announces Updated Results from LOTIS-2 Trial to be Presented at the European Hematology Association 2023 Hybrid Congress adctherapeutics.com ↗
Poster presentation will highlight durable, long-term responses in relapsed/refractory DLBCL patients treated with ZYNLONTA |
| 2022-12-21 | Sobi, Inc. | Regulatory Zynlonta® (loncastuximab tesirine) approved in the EU for the treatment of relapsed or refractory diffuse large B-cell lymphoma sobi.com ↗
Sobi® and ADC Therapeutics SA today announced that the European Commission (EC) has granted conditional marketing authorisation for the use of Zynlonta® (loncastuximab tesirine) for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL). |
| 2022-12-21 | ADC Therapeutics S.A. | Regulatory ADC Therapeutics and Sobi Announce European Commission Approval of ZYNLONTA® (loncastuximab tesirine) for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma adctherapeutics.com ↗
ADC Therapeutics SA (NYSE: ADCT) and Swedish Orphan Biovitrum AB (Sobi ® ) today announced the European Commission (EC) has granted conditional marketing authorization for the use of ZYNLONTA ® (loncastuximab tesirine) for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL). |
| 2022-09-21 | ADC Therapeutics S.A. | Results ADC Therapeutics Announces Abstracts to be Presented at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2022) adctherapeutics.com ↗
The overall response rate by central review was 15/20 (75%). |
| 2022-09-16 | Sobi, Inc. | Regulatory Loncastuximab tesirine receives positive CHMP opinion for the treatment of relapsed or refractory diffuse large B-cell lymphoma sobi.com ↗
The positive opinion from the CHMP is now referred to the European Commission for a decision. |
| 2022-09-16 | ADC Therapeutics S.A. | Regulatory ADC Therapeutics and Sobi Announce ZYNLONTA® (loncastuximab tesirine) Receives Positive CHMP Opinion in Europe for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma adctherapeutics.com ↗
ADC Therapeutics SA (NYSE: ADCT) and Swedish Orphan Biovitrum AB (Sobi®) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion recommending the marketing authorization of ZYNLONTA® (loncastuximab tesirine) for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL). |
| 2022-04-04 | ADC Therapeutics S.A. | Regulatory ADC Therapeutics Receives Permanent J-Code for ZYNLONTA® (J9359) from U.S. Centers for Medicare & Medicaid Services adctherapeutics.com ↗
ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients with hematologic malignancies and solid tumors, announced today that a permanent J-code, J9359, has been issued for ZYNLONTA® by the U.S. Centers for Medicare & Medicaid Services (CMS) effective as of April 1, 2022. |
| 2021-11-04 | ADC Therapeutics S.A. | Results ADC Therapeutics Announces Abstracts to be Presented at the 63rd ASH Annual Meeting adctherapeutics.com ↗
We are also encouraged by the anti-tumor activity and manageable safety profile of ZYNLONTA in combination with ibrutinib. |
| 2021-10-29 | ADC Therapeutics S.A. | Regulatory ADC Therapeutics Announces Validation of its Marketing Authorization Application by the European Medicines Agency for ZYNLONTA® adctherapeutics.com ↗
Validation of the application enables the evaluation process by the EMA’s Committee for Medicinal Products for Human Use (CHMP) to begin. |
| 2021-09-13 | ADC Therapeutics S.A. | Regulatory ADC Therapeutics Receives Orphan Drug Designation in Europe for ZYNLONTA® adctherapeutics.com ↗
ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological malignancies and solid tumors, today announced that the European Commission has granted Orphan Drug Designation to ZYNLONTA®, a CD19-targeted ADC, for the treatment of diffuse large B-cell lymphoma (DLBCL). |
| 2021-06-18 | ADC Therapeutics S.A. | Results ADC Therapeutics Presents Updated ZYNLONTA™ (loncastuximab tesirine-lpyl) Clinical Data at 16th Annual International Conference on Malignant Lymphoma adctherapeutics.com ↗
LOTIS-2 updated results demonstrate durable responses of ZYNLONTA ™ with median duration of response of 13.4 months in heavily pre-treated patients with relapsed or refractory DLBCL |
| 2021-06-04 | ADC Therapeutics S.A. | Results ADC Therapeutics Presents Updated Clinical Data at 2021 ASCO Annual Meeting adctherapeutics.com ↗
In LOTIS-2, a single-arm, open-label, 145-patient Phase 2 clinical trial in patients with relapsed or refractory DLBCL who had failed ≥2 established therapies, ZYNLONTA demonstrated continued substantial antitumor activity and an acceptable safety profile. |
| 2021-05-12 | ADC Therapeutics S.A. | Results ADC Therapeutics Announces Online Publication of LOTIS-2 Results in The Lancet Oncology adctherapeutics.com ↗
The LOTIS-2 study established that ZYNLONTA demonstrated substantial single-agent activity and produced durable responses with an acceptable safety profile in this patient population. |
| 2021-04-23 | ADC Therapeutics S.A. | Regulatory ADC Therapeutics Announces FDA Approval of ZYNLONTA™ (loncastuximab tesirine-lpyl) in Relapsed or Refractory Diffuse Large B-Cell Lymphoma adctherapeutics.com ↗
ZYNLONTA, a CD19-targeted antibody drug conjugate (ADC), has been granted accelerated approval by the FDA based on overall response rate. |
| 2020-12-07 | ADC Therapeutics S.A. | Results ADC Therapeutics Announces Updated Clinical Data on Lead Antibody Drug Conjugate Programs Loncastuximab Tesirine (Lonca) and Camidanlumab Tesirine (Cami) Presented at 62nd American Society of Hematology Annual Meeting adctherapeutics.com ↗
Lonca LOTIS 2 subgroup data include updated median duration of response of 12.58 months |
| 2020-11-20 | ADC Therapeutics S.A. | Regulatory ADC Therapeutics Announces FDA Accepts Biologics License Application and Grants Priority Review for Loncastuximab Tesirine for Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma adctherapeutics.com ↗
the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for loncastuximab tesirine (Lonca) for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and granted priority review status. |
| 2020-09-21 | ADC Therapeutics S.A. | Regulatory ADC Therapeutics Submits Biologics License Application to the U.S. Food and Drug Administration for Loncastuximab Tesirine for Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma adctherapeutics.com ↗
ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid tumors, today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for loncastuximab tesirine (Lonca) for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). |
| 2020-06-12 | ADC Therapeutics S.A. | Results ADC Therapeutics Announces Maturing Data from Pivotal Phase 2 Clinical Trial and Phase 1/2 Combination Clinical Trial of Loncastuximab Tesirine (Lonca) in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma adctherapeutics.com ↗
Lonca demonstrated an overall response rate of 48.3% and complete response rate of 24.1% in the pivotal Phase 2 single-agent trial |
| 2020-01-09 | ADC Therapeutics S.A. | Results ADC Therapeutics Announces Positive Results from Pivotal Phase 2 Clinical Trial of Single Agent Loncastuximab Tesirine (ADCT-402) in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma adctherapeutics.com ↗
Loncastuximab tesirine has demonstrated manageable toxicity in patients with relapsed or refractory DLBCL. |
All press releases naming this drug 54 releases
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 36 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Loncastuximab Tesirine | “Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed/refractory B-cell acute lymphoblastic leukemia.” PMID 32012214 ↗ Feb 2020 |
| Known as | ADCT-402 | “Based on published results we considered the expected 12-month PFS with available treatments to be \<20%; we hypothesized that, in this setting of patients, a consolidation...” NCT05249959 ↗2“The purpose of this phase 1 study is to evaluate the safety and anti-tumor activity of Loncastuximab Tesirine (ADCT-402) and Durvalumab in participants with Advanced Diffuse...” NCT03685344 ↗ |
| Known as | ADCT-402 TESIRINE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297778 ↗ |
| Known as | Lonca | “Loncastuximab tesirine (loncastuximab tesirine-lpyl [Lonca]), an anti-CD19 antibody conjugated to a potent pyrrolobenzodiazepine dimer, demonstrated single-agent antitumor...” PMID 37646659 ↗ Apr 2024 |
| Known as | Loncastuximab tesirina | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297778 ↗ |
| Known as | loncastuximab tesirine-lpyl | “Loncastuximab tesirine (loncastuximab tesirine-lpyl [Lonca]), an anti-CD19 antibody conjugated to a potent pyrrolobenzodiazepine dimer, demonstrated single-agent antitumor...” PMID 37646659 ↗ Apr 2024 |
| Known as | Zynlonta | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297778 ↗ |
| Action | Deplete | “Loncastuximab tesirine has been designed to target and kill CD19-expressing malignant B-cells.” NCT03589469 ↗ |
| Modality | Other / unclassified | “Loncastuximab tesirine is an antibody drug conjugate (ADC) composed of a humanized antibody directed against human cluster of differentiation 19 (CD19)” NCT03589469 ↗ |
| Route | Intravenous | “intravenous infusion” NCT02669017 ↗ |
| Target | CD19 | “comprising a CD19-targeting antibody and pyrrolobenzodiazepine dimers.” PMID 31685491 ↗ Nov 2019 |